Anaïs Makos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anaïs Makos has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Jan Herman Kuiper
Rheumatology Department, Robert Jones and Agnes Hunt Orthopaedic Hospital
2 shared publications Roshan Amarasena
Rheumatology Department, Robert Jones and Agnes Hunt Orthopaedic Hospital
2 shared publications- Akihiro Nakamura
Department of Medicine, Division of Rheumatology, Queen’s University, Kingston, Canada
1 shared publication - Amélie Spangenberg
A. Spangenberg, MBBS, Department of Dermatology, University of California San Francisco, San Francisco, California, USA
1 shared publication - Anna Piccinelli
A. Piccinelli, PhD, Rheumatology Unit, University of Verona, Verona, Italy
1 shared publication - Giovanni Adami
Rheumatology Unit, University of Verona
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 18
Candidate immune signatures predicting TNF-inhibitor outcomes in psoriatic arthritis: A comparative study with rheumatoid arthritis
Background: Tumour necrosis factor inhibitors (TNFi) are widely used to treat psoriatic arthritis (PsA). However, response to TNFi remains variable, and biomarkers of response are needed to guide treatment selection. Cellular and molecular immune signatures may contribute to treatment resistance. This exploratory proof-of-concept study aims to identify candidate immune biomarkers of response to TNFi in PsA, using a cohort of patients with PsA and rheumatoid arthritis (RA) to determine whether these candidate immune biomarkers are disease-specific or shared across inflammatory arthritides. Objectives: To investigate baseline cellular and molecular immune profiles in PsA and RA patients, and to identify, within these profiles, candidate biomarker signatures predictive of TNFi response. Design: Prospective observational cohort study. Methods: 16 PsA, 15 RA, and 19 healthy controls (HC) were included in the study. Immune cells were profiled by multicolour flow cytometry to quantify T helper (Th) subsets, Tregs, NK cells, monocytes, dendritic cells (DC), membrane-bound TNF (mTNF + ) and FcRn + cell populations. Plasma cytokines and chemokines were measured using multiplex and ELISA assays. Treatment response was defined using the PsARC (PsA) or DAS28 (RA) scores at three and six months. Binary/ordinal logistic regressions and linear regression analyses were performed to identify potential associations with treatment response. Considering the small sample size and the large number of candidate predictors assessed, all analyses were exploratory and aimed to generate hypotheses. Results: In PsA, higher baseline Treg proportions and higher Th1/Th17 ratios were associated with higher odds of good TNFi response, whereas increased activated Th17 cells were associated with higher odds of poor response and worse joint outcomes. However, at six months, the association between Th1/Th17 ratios and good response was lost, and higher ratios were associated with higher odds of poorer response, suggesting a potential time-dependent association. Elevated DC proportions were associated with higher odds of poor six-month response. Among molecular markers, IL-13 and TGF-β1 were strongly associated with higher odds of poor three-month response in PsA, while IL-33 showed associations with poorer response and worse tender joint counts at three months post-treatment. In RA, FcRn + T cells, CCL-2, and IL-11 were associated with higher odds of poor response, whereas mTNF + monocytes were associated with higher odds of good response to TNFi at three and six months. Conclusion: Despite the limited statistical power associated with the small cohort size, this exploratory PoC study identified several immune cell and cytokine profiles associated with TNFi response in PsA and RA. These exploratory findings support the investigation of immune biomarker panels that can guide treatment strategy to reduce TNFi failure and discontinuation. However, because of the small sample size of the study, the large number of immune predictors assessed and the exploratory nature of this study, these candidate biomarkers and hypothesis-generating associations should be interpreted with caution and validated in larger, independent cohorts before any predictive or clinical utility can be established.
- 1 August 2026
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 18
Open AccessCandidate immune signatures predicting TNF-inhibitor outcomes in psoriatic arthritis: A comparative study with rheumatoid arthritis
Background: Tumour necrosis factor inhibitors (TNFi) are widely used to treat psoriatic arthritis (PsA). However, response to TNFi remains variable, and biomarkers of response are needed to guide treatment selection. Cellular and molecular immune signatures may contribute to treatment resistance. This exploratory proof-of-concept study aims to identify candidate immune biomarkers of response to TNFi in PsA, using a cohort of patients with PsA and rheumatoid arthritis (RA) to determine whether these candidate immune biomarkers are disease-specific or shared across inflammatory arthritides. Objectives: To investigate baseline cellular and molecular immune profiles in PsA and RA patients, and to identify, within these profiles, candidate biomarker signatures predictive of TNFi response. Design: Prospective observational cohort study. Methods: 16 PsA, 15 RA, and 19 healthy controls (HC) were included in the study. Immune cells were profiled by multicolour flow cytometry to quantify T helper (Th) subsets, Tregs, NK cells, monocytes, dendritic cells (DC), membrane-bound TNF (mTNF + ) and FcRn + cell populations. Plasma cytokines and chemokines were measured using multiplex and ELISA assays. Treatment response was defined using the PsARC (PsA) or DAS28 (RA) scores at three and six months. Binary/ordinal logistic regressions and linear regression analyses were performed to identify potential associations with treatment response. Considering the small sample size and the large number of candidate predictors assessed, all analyses were exploratory and aimed to generate hypotheses. Results: In PsA, higher baseline Treg proportions and higher Th1/Th17 ratios were associated with higher odds of good TNFi response, whereas increased activated Th17 cells were associated with higher odds of poor response and worse joint outcomes. However, at six months, the association between Th1/Th17 ratios and good response was lost, and higher ratios were associated with higher odds of poorer response, suggesting a potential time-dependent association. Elevated DC proportions were associated with higher odds of poor six-month response. Among molecular markers, IL-13 and TGF-β1 were strongly associated with higher odds of poor three-month response in PsA, while IL-33 showed associations with poorer response and worse tender joint counts at three months post-treatment. In RA, FcRn + T cells, CCL-2, and IL-11 were associated with higher odds of poor response, whereas mTNF + monocytes were associated with higher odds of good response to TNFi at three and six months. Conclusion: Despite the limited statistical power associated with the small cohort size, this exploratory PoC study identified several immune cell and cytokine profiles associated with TNFi response in PsA and RA. These exploratory findings support the investigation of immune biomarker panels that can guide treatment strategy to reduce TNFi failure and discontinuation. However, because of the small sample size of the study, the large number of immune predictors assessed and the exploratory nature of this study, these candidate biomarkers and hypothesis-generating associations should be interpreted with caution and validated in larger, independent cohorts before any predictive or clinical utility can be established.
- 15 May 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 28-32
GRAPPA 2025 Annual Meeting: Advances in Psoriatic Disease Research From Pilot Grant Awardees
Key advances from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) pilot research grant program were presented at the GRAPPA 2025 annual meeting. Areas of study included hypoxia-inducible factor 1α (HIF1A) as a potential factor in psoriatic arthritis (PsA), plasma extracellular vesicle cytokines as potential biomarkers for predicting response to tumor necrosis factor inhibitors in PsA, bone properties and biomechanics in psoriatic disease (PsD), better understanding of differences in body composition in PsD, and the effect of sleep on PsD severity.
- 15 May 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 28-32
GRAPPA 2025 Annual Meeting: Advances in Psoriatic Disease Research From Pilot Grant Awardees
Key advances from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) pilot research grant program were presented at the GRAPPA 2025 annual meeting. Areas of study included hypoxia-inducible factor 1α (HIF1A) as a potential factor in psoriatic arthritis (PsA), plasma extracellular vesicle cytokines as potential biomarkers for predicting response to tumor necrosis factor inhibitors in PsA, bone properties and biomechanics in psoriatic disease (PsD), better understanding of differences in body composition in PsD, and the effect of sleep on PsD severity.
- Open Access
- 12 December 2022
- Published by Springer Nature in Inflammopharmacology
- Vol. 31 (1) , 77-87
Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors
Psoriatic arthritis (PsA) is a chronic and painful inflammatory immune-mediated disease. It affects up to 40% of people with psoriasis and it is associated with several comorbidities such as obesity, diabetes, metabolic syndrome, and hypertension. PsA is difficult to diagnose because of its diverse symptoms, namely axial and peripheral arthritis, enthesitis, dactylitis, skin changes, and nail dystrophy. Different drugs exist to treat the inflammation and pain. When patients do not respond to conventional drugs, they are treated with biologic drugs. Tumour necrosis factor inhibitors (TNFi’s) are commonly given as the first biologic drug; beside being expensive, they also lack efficacy in 50% of patients. A biomarker predicting individual patient’s response to TNFi would help treating them earlier with an appropriate biologic drug. This study aimed to review the literature to identify potential biomarkers that should be investigated for their predictive ability. Several such biomarkers were identified, namely transmembrane TNFα (tmTNF), human serum albumin (HSA) and its half-life receptor, the neonatal Fc receptor (FcRn) which is also involved in IgG lifespan; calprotectin, high mobility group protein B1 (HMGB1) and advanced glycation end products (AGEs) whose overexpression lead to excessive production of pro-inflammatory cytokines; lymphotoxin α (LTα) which induces inflammation by binding to TNF receptor (TNFR); and T helper 17 (Th17) cells which induce inflammation by IL-17A secretion.
- 12 December 2022
- Published by Springer Nature in Inflammopharmacology
- Vol. 31 (1) , 77-87
Open AccessPsoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors
Psoriatic arthritis (PsA) is a chronic and painful inflammatory immune-mediated disease. It affects up to 40% of people with psoriasis and it is associated with several comorbidities such as obesity, diabetes, metabolic syndrome, and hypertension. PsA is difficult to diagnose because of its diverse symptoms, namely axial and peripheral arthritis, enthesitis, dactylitis, skin changes, and nail dystrophy. Different drugs exist to treat the inflammation and pain. When patients do not respond to conventional drugs, they are treated with biologic drugs. Tumour necrosis factor inhibitors (TNFi’s) are commonly given as the first biologic drug; beside being expensive, they also lack efficacy in 50% of patients. A biomarker predicting individual patient’s response to TNFi would help treating them earlier with an appropriate biologic drug. This study aimed to review the literature to identify potential biomarkers that should be investigated for their predictive ability. Several such biomarkers were identified, namely transmembrane TNFα (tmTNF), human serum albumin (HSA) and its half-life receptor, the neonatal Fc receptor (FcRn) which is also involved in IgG lifespan; calprotectin, high mobility group protein B1 (HMGB1) and advanced glycation end products (AGEs) whose overexpression lead to excessive production of pro-inflammatory cytokines; lymphotoxin α (LTα) which induces inflammation by binding to TNF receptor (TNFR); and T helper 17 (Th17) cells which induce inflammation by IL-17A secretion.